Clinical Trials Logo

Clinical Trial Summary

Actively developing stem cells (SCs) transplantation techniques cause natural interest to the problem of regeneration in the lungs. Numerous experimental studies proved the benefits of different types of SCs in experimental models of pulmonary emphysema (PE).

G. Zhen et al. have shown that the transplantation of mesenchymal stem cells (MSCs) to rats with papain-induced emphysema leads to their migration into the lungs, differentiation into type 2 alveolocytes, and inhibition of apoptosis and prevention PE.

K. Schweitzer et al. have proved the activity of inflammation in the airways, alveolocytes and endothelial cells apoptosis decreased after adipose SCs intravenous administration to mice with emphysema caused by chronic exposure to tobacco smoke or VEGF receptors blockade. The study of E.P. Ingenito et al. found that endobronchial installed MSCs engraft into the alveolar wall and peribronchial interstitium and release integrins, extracellular matrix components (collagen IV, laminin and fibrillin), platelet-derived growth factor receptor and transforming growth factor β2.

Our study also found reliable deterrent effect of allogeneic bone marrow MSCs on the development of elastase-induced emphysema in rats at different terms of transplantation.

After the success of pilot studies have started clinical trials. Currently, the website http://www. ClinicalTrials.gov reported three studies evaluating the efficacy and safety of MSC transplantation in patients with COPD and emphysema. Two of them have already been completed and the results of the first pilot project published.

Authors on the example of 4 patients showed a complete absence of adverse effects, improved quality of life and stability of functional parameters at 12 months after starting treatment One of the problems of MSC transplantation in patients with respiratory failure is an accelerated apoptosis of transplanted cells under the influence of proinflammatory cytokines and oxidative stress. Since it is proved that preconditioning MSCs under hypoxia increases their survival in hypoxic conditions, increases the expression of growth factors and antiinflammatory cytokines, we suppose that MSCs grown in hypoxic medium may have a significant positive effect on the disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01849159
Study type Interventional
Source Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date March 2014
Completion date June 2017

See also
  Status Clinical Trial Phase
Recruiting NCT00995852 - Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study Phase 2/Phase 3
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00123422 - Innovation in Pulmonary Rehabilitation N/A
Recruiting NCT02879331 - Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils N/A
Completed NCT01507415 - Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD? N/A
Completed NCT01051258 - AeriSeal System for Lung Volume Reduction Phase 1/Phase 2
Completed NCT00680056 - Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients Phase 4
Completed NCT01872624 - Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema N/A
Completed NCT01110252 - Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease N/A
Completed NCT00517998 - Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study Phase 1
Terminated NCT00205920 - Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation Phase 2
Completed NCT01869205 - The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients Phase 3
Terminated NCT01320566 - A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema Phase 2/Phase 3
Completed NCT00683722 - PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Active, not recruiting NCT04465461 - Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion N/A
Completed NCT04012359 - Description of Bullous Emphysema Using Lung Ultrasound and Comparison to the Characteristics of Pneumothorax
Recruiting NCT04918706 - Allogeneic MSC Treatment for Pulmonary Emphysema Phase 2
Terminated NCT01449292 - Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) Phase 3
Completed NCT00347659 - US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study Phase 1
Recruiting NCT02827721 - Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)